Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORIZED REPRESENTATIVE

References are made to (i) the prospectus of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") dated June 29, 2023 which disclosed, amongst others, the appointment of Mr. Zhou Zejian ("**Mr. Zhou**") and Ms. Fung Wai Sum ("**Ms. Fung**") as the joint company secretaries of the Company, the grant of waiver (the "**Initial Waiver**") by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") to the Company from strict compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") for a period of three years from the listing date of the Company (being the period from July 11, 2023 to July 10, 2026), and the appointment of Ms. Fung as one of the authorized representatives of the Company under Rule 3.05 of the Listing Rules ("**Authorized Representative**"); and (ii) the announcement of the Company dated December 6, 2024 in relation to, amongst others, the resignation of Ms. Fung as a joint company secretary of the Company and an Authorized Representative, the appointment of Mr. Chung Ming Fai ("**Mr. Chung**") as a joint company secretary of the Company and an Authorized Representative, and the grant of a new waiver by the Stock Exchange to the Company from strict compliance with Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Initial Waiver.

The board of directors (the "**Board**") of the Company is pleased to announce that the Stock Exchange has confirmed that Mr. Zhou is qualified to act as the company secretary of the Company under Rule 3.28 of the Listing Rules. On July 7, 2026, Mr. Chung tendered his resignation as a joint company secretary of the Company and an Authorized Representative, each with effect from July 11, 2026.

Following the resignation of Mr. Chung, Mr. Zhou will act as the sole company secretary of the Company and an Authorized Representative, each with effect from July 11, 2026.

Mr. Chung has confirmed that he has no disagreement with the Board and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to his resignation as a joint company secretary of the Company and an Authorized Representative.

The Board takes this opportunity to thank Mr. Chung for his valuable contribution to the Company during his term of office.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, July 7, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.